Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression

Movement Disorders

Volumn 26, Issue 9, 2011, Pages 1657-1662

  Remple, Michael S ^a   Bradenham, Courtney H ^a   Kao, C Chris ^a   Charles, P David ^a   Neimat, Joseph S ^a   Konrad, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neurodegeneration; Neurophysiology; Parkinson's disease; Pathophysiology; Rate model; Subthalamic nucleus

Indexed keywords

ADULT; ARTICLE; CELL LOSS; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; NERVE CONDUCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SPIKE; SUBTHALAMIC NUCLEUS;

ACTION POTENTIALS; AGED; DEEP BRAIN STIMULATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICROELECTRODES; MIDDLE AGED; NEURONS; PARKINSON DISEASE; SUBTHALAMIC NUCLEUS;

EID: 79961207952     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23708     Document Type: Article

References (40)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-376.
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375.
3. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-285.
4. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009; 8: 67-81.
5. Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol 2008; 119: 1459-1474.
6. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80: 4546-4550.
7. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984; 292: 390-394.
8. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994; 72: 507-520.
9. Breit S, Bouali-Benazzouz R, Popa RC, Gasser T, Benabid AL, Benazzouz A. Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp Neurol 2007; 205: 36-47.
10. Hassani OK, Mouroux M, Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996; 72: 105-115.
11. Miller WC, DeLong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A, eds. The Basal Ganglia II. New York: Plenum; 1987: 415-427.
12. Wichmann T, Soares J. Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol 2006; 95: 2120-2133.
13. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1438.
14. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993; 5: 382-389.
15. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991; 6: 288-292.
16. Hutchison WD, Allan RJ, Opitz H, et al. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol 1998; 44: 622-628.
17. Magarinos-Ascone CM, Figueiras-Mendez R, Riva-Meana C, Cordoba-Fernandez A. Subthalamic neuron activity related to tremor and movement in Parkinson's disease. Eur J Neurosci 2000; 12: 2597-2607.
18. Rodriguez-Oroz MC, Rodriguez M, Guridi J, et al. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain 2001; 124: 1777-1790.
19. Boraud T, Bezard E, Bioulac B, Gross CE. From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol 2002; 66: 265-283.
20. Steigerwald F, Potter M, Herzog J, et al. Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. J Neurophysiol 2008; 100: 2515-2524.
21. Charles PD, Gill CE, Davis TL, Konrad PE, Benabid AL. Is deep brain stimulation neuroprotective if applied early in the course of PD? Nat Clin Pract Neurol 2008; 4: 424-426.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001; 57(10 Suppl 3): S11-S26.
23. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-463.
24. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007; 30: 256-265.
25. Wullner U, Kassubek J, Odin P, et al. Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm 2010; 117: 855-859.
26. Zonenshayn M, Rezai AR, Mogilner AY, Beric A, Sterio D, Kelly PJ. Comparison of anatomic and neurophysiological methods for subthalamic nucleus targeting. Neurosurgery 2000; 47: 282-292; discussion 292-284.
27. D'Haese PF, Pallavaram S, Konrad PE, Neimat J, Fitzpatrick JM, Dawant BM. Clinical accuracy of a customized stereotactic platform for deep brain stimulation after accounting for brain shift. Stereotact Funct Neurosurg 2010; 88: 81-87.
28. Fitzpatrick JM, Konrad PE, Nickele C, Cetinkaya E, Kao C. Accuracy of customized miniature stereotactic platforms. Stereotact Funct Neurosurg 2005; 83: 25-31.
29. Gross RE, Krack P, Rodriguez-Oroz MC, Rezai AR, Benabid AL. Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov Disord 2006; 21(Suppl 14): S259-S283.
30. Benazzouz A, Breit S, Koudsie A, Pollak P, Krack P, Benabid AL. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002; 17(Suppl 3): S145-S149.
31. Magnin M, Morel A, Jeanmonod D. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience 2000; 96: 549-564.
32. Hutchinson WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 1997; 42: 767-775.
33. Robin K, Maurice N, Degos B, Deniau JM, Martinerie J, Pezard L. Assessment of bursting activity and interspike intervals variability: a case study for methodological comparison. J Neurosci Methods 2009; 179: 142-149.
34. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990; 85: 119-146.
35. Elias WJ, Durieux ME, Huss D, Frysinger RC. Dexmedetomidine and arousal affect subthalamic neurons. Mov Disord 2008; 23: 1317-1320.
36. Rozet I, Muangman S, Vavilala MS, et al. Clinical experience with dexmedetomidine for implantation of deep brain stimulators in Parkinson's disease. Anesth Analg 2006; 103: 1224-1228.
37. Bekker A, Sturaitis MK. Dexmedetomidine for neurological surgery. Neurosurgery 2005; 57(1 Suppl): 1-10; discussion 10-11.
38. Ni ZG, Bouali-Benazzouz R, Gao DM, Benabid AL, Benazzouz A. Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res 2001; 899: 142-147.
39. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561-573.
40. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007; 2: 234-243.